Odronextamab

Therapeutic indications

Odronextamab is indicated for:

Relapsed or refractory follicular lymphoma

Population group: only adults (18 years old or older)

Odronextamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.2-10 mg step-up dosing on Cycle 1, 80 mg on Day 1, 8 and 15 of Cycles 2 to 4, and thereafter 160 mg every 2 weeks

Relapsed or refractory diffuse large B-cell lymphoma

Population group: only adults (18 years old or older)

Odronextamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.2-10 mg step-up dosing on Cycle 1, 160 mg on Day 1, 8 and 15 of Cycles 2 to 4, and thereafter 320 mg every 2 weeks

Contraindications

Odronextamab is contraindicated in the following cases:

Lactation

Live vaccines

Live organism vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.